Review



cd40l thermofisher scientific, clone mr1  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Thermo Fisher cd40l thermofisher scientific, clone mr1
    Cd40l Thermofisher Scientific, Clone Mr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/anti+f4+80/pm40558509-90-7-8
    Average 90 stars, based on 1 article reviews
    cd40l thermofisher scientific, clone mr1 - by Bioz Stars, 2026-09
    90/100 stars

    Images



    Similar Products

    90
    Thermo Fisher cd40l thermofisher scientific, clone mr1
    Cd40l Thermofisher Scientific, Clone Mr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/anti+f4+80/pm40558509-90-7-8
    Average 90 stars, based on 1 article reviews
    cd40l thermofisher scientific, clone mr1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    Bio X Cell mr1
    Immunomodulatory agents do not affect viability of TM3-Venus-Akaluc cells. MTT cytotoxicity assay assessing viability of TM3-Venus-Akaluc cells following incubation with low or high concentrations of individual immunomodulatory agents at either 48 or 72 h post treatment: (A) CCL22 (low: 3 μg/mL, high: 15 μg/mL), (B) IL-2 (low: 0.6 μg/mL, high: 3 μg/mL), (C) JES6 (low: 3 μg/mL, high: 1.5 μg/mL), (D) <t>MR1</t> (low: 3 μg/mL, high: 15 μg/mL), (E) anti-CD8 (low: 6 μg/mL, high: 30 μg/mL), (F) combined cocktail of all agents at the concentrations listed above. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.001. Data represent mean ± SD from six biological replicates. Statistical significance determined via two-way ANOVA.
    Mr1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/InVivoPlus+anti-mouse+CD40L/pmc12657320-100-1-7
    Average 93 stars, based on 1 article reviews
    mr1 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    fluidigm cd40l mr1 170er cytof standard biotools 3170011b
    Immunomodulatory agents do not affect viability of TM3-Venus-Akaluc cells. MTT cytotoxicity assay assessing viability of TM3-Venus-Akaluc cells following incubation with low or high concentrations of individual immunomodulatory agents at either 48 or 72 h post treatment: (A) CCL22 (low: 3 μg/mL, high: 15 μg/mL), (B) IL-2 (low: 0.6 μg/mL, high: 3 μg/mL), (C) JES6 (low: 3 μg/mL, high: 1.5 μg/mL), (D) <t>MR1</t> (low: 3 μg/mL, high: 15 μg/mL), (E) anti-CD8 (low: 6 μg/mL, high: 30 μg/mL), (F) combined cocktail of all agents at the concentrations listed above. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.001. Data represent mean ± SD from six biological replicates. Statistical significance determined via two-way ANOVA.
    Cd40l Mr1 170er Cytof Standard Biotools 3170011b, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/Anti-Mouse+CD154%2FCD40+Ligand+(MR1)-170Er/pmc10182775__JEM_20220509_TableS1-1-200-204
    Average 93 stars, based on 1 article reviews
    cd40l mr1 170er cytof standard biotools 3170011b - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-cd40l pe mr1
    Resource used in this study.
    Anti Cd40l Pe Mr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/pe+labeled+goat+anti+human+igg/pmc11910518-6-3-5
    Average 90 stars, based on 1 article reviews
    anti-cd40l pe mr1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    99
    Thermo Fisher cd40l intracellular percp efluor710 mr1
    Resource used in this study.
    Cd40l Intracellular Percp Efluor710 Mr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/SUCROSE+EP%2FBP%2FNF+12KG/pmc11357811__mmc2-347-55-54
    Average 99 stars, based on 1 article reviews
    cd40l intracellular percp efluor710 mr1 - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    90
    Bio X Cell anti cd40l mr1
    Resource used in this study.
    Anti Cd40l Mr1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/anti+cd40l/ppr0852253-319-12-15
    Average 90 stars, based on 1 article reviews
    anti cd40l mr1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Bio X Cell cd40l-blocking antibody clone mr1
    Resource used in this study.
    Cd40l Blocking Antibody Clone Mr1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/anti+cd40l/pmc11074383-270-1-9
    Average 90 stars, based on 1 article reviews
    cd40l-blocking antibody clone mr1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Bio X Cell anti-cd40l antibody mr1
    Resource used in this study.
    Anti Cd40l Antibody Mr1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/anti+cd40l/pm38329123-171-16-36
    Average 90 stars, based on 1 article reviews
    anti-cd40l antibody mr1 - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    92
    Bio X Cell mr1 anti mouse cd40l blocking mab
    a Comparison of the total number of intrahepatic effector gBT-1 T cells at 14 days post-rAAV treatment in recipient mice treated with anti-CD4 depleting, <t>anti-CD40L</t> blocking Ab, or isotype control Ab. b Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of recipient mice treated with isotype control, or <t>CD40L</t> blocking Abs beginning day 0 or day 9 post-rAAV. c Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of CD4-depleted recipient mice administered agonist anti-CD40 mAb or isotype control 9-days post-rAAV. d Representative IF image of a portal tract cluster containing transferred gBT-1 and P25 T cells interacting with MHCII high cells in the liver 12-days post-rAAV treatment of recipient mice. Data are representative of two independent experiments. n = 4 ( a ) or n = 5 ( b ), n = 4 or 5 ( c ), n = 3 mice per group. Error bars indicate ± SEM. Analysed with one-way ANOVA with Tukey’s multiple comparisons test ( a , b ), or a two-tailed Student’s t test (c). Scale bars, 40 μm/20 μm ( d ). Source data are provided as a Source Data file.
    Mr1 Anti Mouse Cd40l Blocking Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/RecombiMAb+anti-mouse+CD40L/pmc10858872-241-12-17
    Average 92 stars, based on 1 article reviews
    mr1 anti mouse cd40l blocking mab - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    93
    Bio X Cell anti cd154 bio x cell mr1
    a Comparison of the total number of intrahepatic effector gBT-1 T cells at 14 days post-rAAV treatment in recipient mice treated with anti-CD4 depleting, <t>anti-CD40L</t> blocking Ab, or isotype control Ab. b Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of recipient mice treated with isotype control, or <t>CD40L</t> blocking Abs beginning day 0 or day 9 post-rAAV. c Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of CD4-depleted recipient mice administered agonist anti-CD40 mAb or isotype control 9-days post-rAAV. d Representative IF image of a portal tract cluster containing transferred gBT-1 and P25 T cells interacting with MHCII high cells in the liver 12-days post-rAAV treatment of recipient mice. Data are representative of two independent experiments. n = 4 ( a ) or n = 5 ( b ), n = 4 or 5 ( c ), n = 3 mice per group. Error bars indicate ± SEM. Analysed with one-way ANOVA with Tukey’s multiple comparisons test ( a , b ), or a two-tailed Student’s t test (c). Scale bars, 40 μm/20 μm ( d ). Source data are provided as a Source Data file.
    Anti Cd154 Bio X Cell Mr1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd40l+(mr1/RecombiMAb+anti-mouse+CD40L/pmc10972596-144-14-15
    Average 93 stars, based on 1 article reviews
    anti cd154 bio x cell mr1 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Immunomodulatory agents do not affect viability of TM3-Venus-Akaluc cells. MTT cytotoxicity assay assessing viability of TM3-Venus-Akaluc cells following incubation with low or high concentrations of individual immunomodulatory agents at either 48 or 72 h post treatment: (A) CCL22 (low: 3 μg/mL, high: 15 μg/mL), (B) IL-2 (low: 0.6 μg/mL, high: 3 μg/mL), (C) JES6 (low: 3 μg/mL, high: 1.5 μg/mL), (D) MR1 (low: 3 μg/mL, high: 15 μg/mL), (E) anti-CD8 (low: 6 μg/mL, high: 30 μg/mL), (F) combined cocktail of all agents at the concentrations listed above. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.001. Data represent mean ± SD from six biological replicates. Statistical significance determined via two-way ANOVA.

    Journal: Materials Today Bio

    Article Title: Generating tolerance through in situ recruitment of regulatory T cells for allogeneic cell transplantation in a bioengineered lymphoid platform

    doi: 10.1016/j.mtbio.2025.102469

    Figure Lengend Snippet: Immunomodulatory agents do not affect viability of TM3-Venus-Akaluc cells. MTT cytotoxicity assay assessing viability of TM3-Venus-Akaluc cells following incubation with low or high concentrations of individual immunomodulatory agents at either 48 or 72 h post treatment: (A) CCL22 (low: 3 μg/mL, high: 15 μg/mL), (B) IL-2 (low: 0.6 μg/mL, high: 3 μg/mL), (C) JES6 (low: 3 μg/mL, high: 1.5 μg/mL), (D) MR1 (low: 3 μg/mL, high: 15 μg/mL), (E) anti-CD8 (low: 6 μg/mL, high: 30 μg/mL), (F) combined cocktail of all agents at the concentrations listed above. ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.001. Data represent mean ± SD from six biological replicates. Statistical significance determined via two-way ANOVA.

    Article Snippet: The MR1 (anti-CD40L) and anti-CD8 monoclonal antibodies (Bio X Cell, New Hampshire, USA) were stored at concentrations ranging from 5 mg/mL to 10 mg/mL, as provided by the manufacturer.

    Techniques: Cytotoxicity Assay, Incubation

    Resource used in this study.

    Journal: Scientific Reports

    Article Title: Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody

    doi: 10.1038/s41598-025-87344-6

    Figure Lengend Snippet: Resource used in this study.

    Article Snippet: Anti-CD40L PE , MR1 , eBioscience.

    Techniques: Flow Cytometry, Adjuvant, Sequencing, Software

    a Comparison of the total number of intrahepatic effector gBT-1 T cells at 14 days post-rAAV treatment in recipient mice treated with anti-CD4 depleting, anti-CD40L blocking Ab, or isotype control Ab. b Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of recipient mice treated with isotype control, or CD40L blocking Abs beginning day 0 or day 9 post-rAAV. c Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of CD4-depleted recipient mice administered agonist anti-CD40 mAb or isotype control 9-days post-rAAV. d Representative IF image of a portal tract cluster containing transferred gBT-1 and P25 T cells interacting with MHCII high cells in the liver 12-days post-rAAV treatment of recipient mice. Data are representative of two independent experiments. n = 4 ( a ) or n = 5 ( b ), n = 4 or 5 ( c ), n = 3 mice per group. Error bars indicate ± SEM. Analysed with one-way ANOVA with Tukey’s multiple comparisons test ( a , b ), or a two-tailed Student’s t test (c). Scale bars, 40 μm/20 μm ( d ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs

    doi: 10.1038/s41467-024-45612-5

    Figure Lengend Snippet: a Comparison of the total number of intrahepatic effector gBT-1 T cells at 14 days post-rAAV treatment in recipient mice treated with anti-CD4 depleting, anti-CD40L blocking Ab, or isotype control Ab. b Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of recipient mice treated with isotype control, or CD40L blocking Abs beginning day 0 or day 9 post-rAAV. c Comparison of the total number of intrahepatic effector gBT-1 T cells at 15 days post-rAAV treatment of CD4-depleted recipient mice administered agonist anti-CD40 mAb or isotype control 9-days post-rAAV. d Representative IF image of a portal tract cluster containing transferred gBT-1 and P25 T cells interacting with MHCII high cells in the liver 12-days post-rAAV treatment of recipient mice. Data are representative of two independent experiments. n = 4 ( a ) or n = 5 ( b ), n = 4 or 5 ( c ), n = 3 mice per group. Error bars indicate ± SEM. Analysed with one-way ANOVA with Tukey’s multiple comparisons test ( a , b ), or a two-tailed Student’s t test (c). Scale bars, 40 μm/20 μm ( d ). Source data are provided as a Source Data file.

    Article Snippet: To block CD40L in vivo, mice were injected i.v. with 500 μg MR1 anti-mouse CD40L blocking mAb (BioXcell, West Lebanon, USA) or polyclonal Armenian hamster IgG isotype control (BioXcell, West Lebanon, USA) in PBS at the indicated time points.

    Techniques: Comparison, Blocking Assay, Control, Two Tailed Test

    a – c Representative confocal IF images of the liver of XCR1 Venus/+ rAAV-treated recipient mice at 12-days post rAAV, showing large clusters of XCR1 + cDC1s, gBT-1 and P25 T cells in PT regions Scale bars 50 μm ( a ), 30 μm ( b ), 4 μm/2 μm ( c ). d , e Quantification of the average distance (μm) separating XCR1 + cells with gBT-1 T cells and ( d ), or with P25 T cells ( e ) in portal tracts (PT), peri-central vein (PCV) and sinusoidal (S) liver regions. Data points represent a single region of interest from n = 7 mice from 2 independent experiments. f , g Hepatic XCR1 + cDC1 isolated from recipient mice treated, 12-days prior, with rAAV gB-Ag85b or PBS, were assessed for their ability to activate and induce proliferation (assessed by CD44 upregulation and CTV dilution), of naive gBT-1 ( f ) or P25 ( g ) T cells co-cultured for 72 h. h , i Same as ( f , g ) but recipient mice were also treated with isotype control (black) or anti-CD40L blocking mAb (red) to assess the role of CD40/CD40L interactions. Representative flow plots ( h ), and proportion of proliferating CD44 high CTV low gBT-1 T cells ( i ). j Co-stimulatory molecule expression levels in hepatic cDC1s isolated from rAAV gB-Ag85b –treated mice that also received isotype control (black) or anti-CD4 depleting mAb (red) at 12-days post rAAV. k , l Quantification of Ki67 + gB T-1 T cell numbers forming clusters in PT ( k ) and PCV regions ( l ) at 12-days post-rAAV treatment in XCR1 +/+ (black) and XCR1 DTR/+ (red) recipient mice treated with DTx, 9-days prior. m , n Quantification of total numbers of intrahepatic ( m ) and splenic ( n ) effector gBT-1 cell in recipient mice treated with rAAV, 15-days prior. Comparison between diphtheria toxin treated XCR1 +/+ (black) and XCR1 DTR/+ (red) recipient mice at 9-days post-rAAV.Data representative of two independent experiments. n = 5 ( a – c ), n = 7 ( d , e ), n = 3 or 4 ( f , g ), n = 7 ( i ), n = 4 ( j ) n = 5 ( k , l ) and n = 6 ( m , n ) mice per group. Error bars indicate ± SEM. Analysed with a Kruskal-Wallis test with multiple comparisons ( d , e ), a two-tailed unpaired Student’s t test ( i , j ) or a two tailed unpaired Mann–Whitney U test ( k – n ); ns not statistically significant. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs

    doi: 10.1038/s41467-024-45612-5

    Figure Lengend Snippet: a – c Representative confocal IF images of the liver of XCR1 Venus/+ rAAV-treated recipient mice at 12-days post rAAV, showing large clusters of XCR1 + cDC1s, gBT-1 and P25 T cells in PT regions Scale bars 50 μm ( a ), 30 μm ( b ), 4 μm/2 μm ( c ). d , e Quantification of the average distance (μm) separating XCR1 + cells with gBT-1 T cells and ( d ), or with P25 T cells ( e ) in portal tracts (PT), peri-central vein (PCV) and sinusoidal (S) liver regions. Data points represent a single region of interest from n = 7 mice from 2 independent experiments. f , g Hepatic XCR1 + cDC1 isolated from recipient mice treated, 12-days prior, with rAAV gB-Ag85b or PBS, were assessed for their ability to activate and induce proliferation (assessed by CD44 upregulation and CTV dilution), of naive gBT-1 ( f ) or P25 ( g ) T cells co-cultured for 72 h. h , i Same as ( f , g ) but recipient mice were also treated with isotype control (black) or anti-CD40L blocking mAb (red) to assess the role of CD40/CD40L interactions. Representative flow plots ( h ), and proportion of proliferating CD44 high CTV low gBT-1 T cells ( i ). j Co-stimulatory molecule expression levels in hepatic cDC1s isolated from rAAV gB-Ag85b –treated mice that also received isotype control (black) or anti-CD4 depleting mAb (red) at 12-days post rAAV. k , l Quantification of Ki67 + gB T-1 T cell numbers forming clusters in PT ( k ) and PCV regions ( l ) at 12-days post-rAAV treatment in XCR1 +/+ (black) and XCR1 DTR/+ (red) recipient mice treated with DTx, 9-days prior. m , n Quantification of total numbers of intrahepatic ( m ) and splenic ( n ) effector gBT-1 cell in recipient mice treated with rAAV, 15-days prior. Comparison between diphtheria toxin treated XCR1 +/+ (black) and XCR1 DTR/+ (red) recipient mice at 9-days post-rAAV.Data representative of two independent experiments. n = 5 ( a – c ), n = 7 ( d , e ), n = 3 or 4 ( f , g ), n = 7 ( i ), n = 4 ( j ) n = 5 ( k , l ) and n = 6 ( m , n ) mice per group. Error bars indicate ± SEM. Analysed with a Kruskal-Wallis test with multiple comparisons ( d , e ), a two-tailed unpaired Student’s t test ( i , j ) or a two tailed unpaired Mann–Whitney U test ( k – n ); ns not statistically significant. Source data are provided as a Source Data file.

    Article Snippet: To block CD40L in vivo, mice were injected i.v. with 500 μg MR1 anti-mouse CD40L blocking mAb (BioXcell, West Lebanon, USA) or polyclonal Armenian hamster IgG isotype control (BioXcell, West Lebanon, USA) in PBS at the indicated time points.

    Techniques: Isolation, Cell Culture, Control, Blocking Assay, Expressing, Comparison, Two Tailed Test, MANN-WHITNEY